Company news

Karyopharm Therapeutics Inc. news in 2023

Karyopharm Therapeutics Inc.'s news releases, calls and decks from 2023, newest first.

View company

Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)

December 9, 2023

Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study

November 5, 2023

Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

November 1, 2023

Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)

November 1, 2023

Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma

October 29, 2023

Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023

October 25, 2023

Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings

September 25, 2023

Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors

August 31, 2023

Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

August 1, 2023

Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023

July 25, 2023

Karyopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer

July 24, 2023

Karyopharm Announces Updated Exploratory Subgroup Analysis from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer to be Presented at ASCO Plenary Series on July 25th

July 18, 2023

Karyopharm Receives FDA Fast Track Designation for Selinexor for the Treatment of Myelofibrosis

July 16, 2023

Karyopharm Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve Myelofibrosis

June 27, 2023

Karyopharm to Participate at the Jefferies Healthcare Conference

May 31, 2023

Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings

May 22, 2023

Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 3, 2023

Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDS

May 2, 2023

Karyopharm to Report First Quarter 2023 Financial Results on May 4, 2023

April 30, 2023

Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at AACR 2023

April 17, 2023

Karyopharm Announces Updated Selinexor Data in Patients with Treatment-Naïve Myelofibrosis to be Presented at AACR 2023

March 13, 2023

Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multip...

February 20, 2023

Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

February 14, 2023

Karyopharm to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023

February 7, 2023

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives

January 8, 2023

Calls in 2023

Decks in 2023